Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
S-8184 Paclitaxel Injectable Emulsion · 4 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| S-8184 Paclitaxel Injectable Emulsion | DRUG | - |
| Experimental Arm: TOCOSOL Paclitaxel | DRUG | Doses of 80, 100 and 120mg/m2 |
Inclusion Criteria: Histologic diagnosis of non small cell lung cancer Relapsed or unresectable stage IIIB or IV disease One and only one prior cytotoxic chemotherapy regimen which must have included a platinum agent dosed at 60 mg/m2 or higher per cycle for cisplatin and AUC 6 per cycle for carb...
S-8184 Paclitaxel Injectable Emulsion is an investigational small-molecule oncology drug developed by Achieve Life Sciences, Inc. It is a formulation of paclitaxel delivered as an injectable emulsion and has been studied in Phase 2 trials across several solid tumor types, including non-small-cell lung cancer, colorectal adenocarcinoma, ovarian cancer, and urologic neoplasms.
S-8184 Paclitaxel Injectable Emulsion has been studied for second-line treatment of several advanced cancers: stage IIIB or IV non-small-cell lung cancer, stage III or IV colorectal adenocarcinoma, stage III or IV ovarian cancer, and transitional cell carcinoma of the urothelium. These were Phase 2 investigations; the drug is not established as an approved therapy.
S-8184 Paclitaxel Injectable Emulsion is developed by Achieve Life Sciences, Inc., which trades under the ticker QUIT. The company sponsored the Phase 2 clinical program evaluating the agent in non-small-cell lung cancer, colorectal adenocarcinoma, ovarian cancer, and urologic neoplasms.
S-8184 Paclitaxel Injectable Emulsion is in Phase 2 development. Its clinical program consists of completed Phase 2 safety and efficacy trials in non-small-cell lung cancer, colorectal adenocarcinoma, ovarian cancer, and transitional cell carcinoma of the urothelium. The drug remains investigational and is not an approved product.
S-8184 Paclitaxel Injectable Emulsion has been evaluated in completed Phase 2 trials: NCT00034190 in second-line colorectal adenocarcinoma, NCT00034177 in transitional cell carcinoma of the urothelium, NCT00034164 in relapsed stage IIIB or IV non-small-cell lung cancer, and NCT00034151 in stage III or IV ovarian cancer. All were single-arm studies.
S-8184 Paclitaxel Injectable Emulsion was studied in four completed Phase 2 trials, each an uncontrolled, non-randomized design enrolling adults aged 18 and older. The ovarian cancer trial enrolled women only. Trial sizes ranged from 27 to 52 participants, and the non-small-cell lung and colorectal studies were conducted in Russia.